Circulating miRNAs are correlated with tumor progression in prostate cancer

By J. C. Brase, Marc Johannes, T. Schlomm, Maria Fälth, A. Haese*, T. Steuber, T. Beissbarth, R. Kuner, H. Sültmann. International Journal of Cancer, 2011

603 citations recorded by the source corpus.

Circulating miRNAs have recently been indicated as practicable and promising biomarkers for noninvasive diagnosis in various tumor entities. However, cell‐free miRNAs have not been found to correlate with clinicopathological variables in epithelial carcinomas. To learn more about the potential clinical relevance of circulating miRNAs in prostate cancer, we screened 667 miRNAs in serum samples from patients with metastatic (n = 7) and localized prostate cancer (n = 14). Various miRNAs were highly abundant in the sera of patients with metastatic disease, and five upregulated miRNAs (miRNA‐375, miRNA‐9*, miRNA‐141, miRNA‐200b and miRNA‐516a‐3p) were selected for further validation. In the first validation study (n = 45), selected miRNAs were analyzed in a prospectively collected serum set taken from different prostate cancer risk groups. Most of the selected miRNAs were significantly correlated with adverse risk factors when different clinicopathological variables were analyzed. Circulating miRNA‐375 and miRNA‐141 turned out to be the most pronounced markers for high‐risk tumors. Their levels also correlated with high Gleason score or lymph‐node positive status in a second independent validation study (n = 71). In addition, the expression levels of miRNA‐375 and miRNA‐141 were monitored in 72 prostate tissue samples (36 tumor vs. 36 benign). Both miRNAs were highly expressed in all samples and significantly upregulated in the tumors compared to normal tissues. Overall, our observations suggest that miRNA‐375 and miRNA‐141 expression is enhanced in prostate cancer specimens and their release into the blood is further associated with advanced cancer disease.

Subfields: Cancer Research, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/eba1c11f998f1103396db952be248938ca5acf6e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. F. Collino
2. Xiaoyi Huang
3. C. Pritchard
4. Cristina Grange
5. M. Deregibus
6. G. Camussi
7. Tiezheng Yuan
8. Marta Tapparo

Citations in the corpus

• Exosomal miR-1290 and miR-375 as Prognostic Markers in Castration-resistant Prostate Cancer (2014, background): “Circulating microRNA (miRNA)-375 and miRNA-141 are correlated with a high Gleason score or lymph-node positive status [10,11], implying great potential as a PCa biomarker.”
• Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies (2011, methodology): “We used qRT-PCR to examine expression of 79 miRNAs reported as circulating solid tumor biomarkers in purified sub-populations of blood cells and in matched healthy donor plasma (9-13) (Fig.”
• Changes in circulating microRNA levels associated with prostate cancer (2012, background): “…of the use of miR-141 and miR375 as markers of metastatic prostate cancer using independent exosomal and microvesicle samples corroborates evidence from other studies implicating miR-141 and miR-375 as useful candidate markers of a metastatic prostate cancer signature (Brase et al, 2011).”
• Microvesicles released from human renal cancer stem cells stimulate angiogenesis and formation of lung premetastatic niche. (2011, background): “Among the miRNAs shuttled by CD105þ MVs, we detected miR-200c, miR-92, and miR-141 that were described significantly upregulated in patients with ovarian (28, 41), colorectal (42), and prostate cancer (43), respectively.”